
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
An all-electronic validation can provide storage costs savings and ensured document legibility.
almost 24 years ago
Regulatory Compliance Training: Who Needs It?





